

SILVA PHARMACEUTICALS LTD
Statement of Financial Position
At 31 March 2025

Particulars	Amount	Amount
ASSETS		
Non-current Assets		
Property, Plant & Equipment	1,200,000	1,200,000
Intangible Assets	500,000	500,000
Current Assets		
Stocks	300,000	300,000
Debtors	200,000	200,000
Prepaid Expenses	50,000	50,000
Cash	150,000	150,000
LIABILITIES		
Current Liabilities		
Creditors	100,000	100,000
Accruals	50,000	50,000
Share Capital	1,000,000	1,000,000
Reserves	400,000	400,000

Silva Pharmaceuticals Limited

Un-Audited Financial Statements (Third Quarter)

For the Period from 01 July, 2024 to 31 March, 2025


Income Statement		
Revenue	1,500,000	1,500,000
Cost of Sales	(800,000)	(800,000)
Gross Profit	700,000	700,000
Operating Expenses	(300,000)	(300,000)
Operating Profit	400,000	400,000
Finance Income	20,000	20,000
Finance Expenses	(10,000)	(10,000)
Profit Before Tax	410,000	410,000
Income Tax	(50,000)	(50,000)
Profit After Tax	360,000	360,000
Dividends Paid	(100,000)	(100,000)
Retained Profit	260,000	260,000
Balance Sheet		
Share Capital	1,000,000	1,000,000
Reserves	400,000	400,000
Non-current Assets	1,700,000	1,700,000
Current Assets	650,000	650,000
Current Liabilities	(150,000)	(150,000)
Net Assets	2,200,000	2,200,000

Notes to the Financial Statements		
1. General Information		
2. Accounting Policies		
3. Revenue		
4. Cost of Sales		
5. Operating Expenses		
6. Finance Income		
7. Finance Expenses		
8. Income Tax		
9. Dividends		
10. Related Party Transactions		
11. Management Discussion and Analysis		

SILVA PHARMACEUTICALS LTD.
Statement of Financial Position (Un-Audited)
As at 31 March, 2025

Particulars	Notes	Amount in Taka	
		31-Mar-25	30-Jun-24
ASSETS			
Non Current Assets		1,435,397,616	1,474,712,706
Property, Plant & Equipment	3.00	1,106,728,023	1,150,164,643
Intangible Assets	4.00	1,132,790	1,224,638
Right-of-use asset (ROU)	5.00	4,672,663	5,651,962
Capital work-in-Progress	6.00	322,864,140	317,671,463
		890,266,792	939,515,718
Current Assets			
Inventories	7.00	446,636,812	493,201,611
Trade and Other Receivables	8.00	246,961,843	256,130,421
Advances, Deposits and Prepayments	9.00	56,229,528	62,689,093
Fixed Deposits Receipts (FDR)	10.00	83,906,788	88,801,678
Cash and Cash Equivalents	11.00	56,531,821	38,692,915
		2,325,664,408	2,414,228,424
Total Assets			
SHAREHOLDERS EQUITY AND LIABILITIES:			
Equity attributable to the Shareholders		2,171,526,132	2,255,949,495
Share Capital	12.00	1,365,000,000	1,365,000,000
Retained Earnings	13.00	806,526,132	890,949,495
		83,675,320	84,114,522
Non-Current Liabilities			
Deferred Tax Liabilities	14.00	81,077,583	80,678,988
Lease liabilities	15.00	2,597,737	3,435,534
		70,462,956	74,164,407
Current Liabilities			
Lease liabilities	15.00	1,074,926	1,182,428
Trade and Other Payables	16.00	8,335,307	7,162,713
Unclaimed Dividend Account	17.00	209,482	176,686
Short Term Finance	18.00	37,794,429	47,709,074
Provision for Expenses	19.00	23,048,812	17,933,506
		154,138,276	158,278,929
Total Liabilities			
Total Equity & Liabilities:		2,325,664,408	2,414,228,424
Net Assets Value (NAV) per share	29.00	15.91	16.53
Number of Shares used to compute NAV		136,500,000	136,500,000

The annexed notes from an integral part of these financial statements.



Chairman



Managing Director / CEO (CC)



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: April 28, 2025


Silva Pharmaceuticals Ltd

Statements of Profit or Loss and Other Comprehensive Income (Un-Audited)

For the Third Quarter ended 31 March, 2025

Particulars	Notes	Amount in Taka			
		Third Quarter ended Results		Quarterly Results	
		01/07/2024 to 31/03/2025	01/07/2023 to 31/03/2024	01/01/2025 to 31/03/2025	01/01/2024 to 31/03/2024
Revenue from Net Sales	20.00	309,278,213	477,253,256	107,643,330	174,288,258
Cost of goods sold	21.00	(208,053,777)	(330,865,907)	(66,507,840)	(114,241,833)
Gross Profit		101,224,436	146,387,349	41,135,490	60,046,425
Operating expenses		(176,401,278)	(155,340,691)	(58,236,113)	(53,331,906)
Administrative Expenses	22.00	(31,355,003)	(28,123,758)	(10,182,642)	(9,521,397)
Selling & Distribution Expenses	23.00	(145,046,275)	(127,216,933)	(48,053,471)	(43,810,509)
Operating Income		(75,176,842)	(8,953,342)	(17,100,623)	6,714,519
Financial expenses	24.00	(3,505,820)	(2,415,421)	(1,569,483)	(1,293,661)
Interest and Other income	25.00	4,971,744	4,245,357	1,606,251	1,703,996
Profit before WPPF and Welfare Fund		(73,710,918)	(7,123,406)	(17,063,855)	7,124,854
Workers' Profit Participation and Welfare Fund (WPP&WF)	26.00	-	-	-	-
Profit before Income Tax		(73,710,918)	(7,123,406)	(17,063,855)	7,124,854
Income Tax Expenses:	27.00	(3,965,940)	(3,475,720)	(1,576,670)	(1,507,371)
Current Tax Expenses	27.01	(3,567,345)	(2,888,992)	(1,452,013)	(1,055,954)
Deferred Tax (expenses)/ Income	27.02	(398,595)	(586,728)	(124,657)	(451,417)
Net Profit after tax		(77,676,858)	(10,599,126)	(18,640,525)	5,617,483
Other Comprehensive Income		-	-	-	-
Total comprehensive income for the period		(77,676,858)	(10,599,126)	(18,640,525)	5,617,483
Earnings Per Share (EPS)	28.00	(0.57)	(0.08)	(0.14)	0.04
Number of Shares used to compute EPS		136,500,000	136,500,000	136,500,000	136,500,000


The annexed notes from an integral part of these financial statements.



Chairman



Managing Director / CEO (CC)



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: April 28, 2025


SILVA PHARMACEUTICALS LTD.
Statement of Changes in Equity (Un-Audited)
For the Third Quarter ended 31 March, 2025


Particulars	(Amount in Taka)		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2024	1,365,000,000	890,949,495	2,255,949,495
Net profit after tax during the period	-	(77,676,858)	(77,676,858)
Dividend for the year 2023-2024	-	(6,746,505)	(6,746,505)
Balance as at 31 March, 2025	1,365,000,000	806,526,132	2,171,526,132


For the Third Quarter ended 31 March, 2024


Particulars	(Amount in Taka)		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2023	1,365,000,000	969,084,309	2,334,084,309
Net profit after tax during the period	-	(10,599,126)	(10,599,126)
Dividend Paid in Cash	-	(13,650,000)	(13,650,000)
Balance as at 31 March, 2024	1,365,000,000	944,835,183	2,309,835,183

The annexed notes from an integral part of these financial statements.


Chairman


Managing Director / CEO (CC)


Director


Chief Financial Officer

Place: Dhaka;
Dated: April 28, 2025


Company Secretary


SILVA PHARMACEUTICALS LTD.
Statement of Cash Flows (Un-Audited)
For the Third Quarter ended 31 March, 2025

Particulars	Notes	Amount in Taka	
		01/07/2024 to 31/03/2025	01/07/2023 to 31/03/2024
Cash flows from Operating Activities			
Cash received from Customers	30.00	319,008,559	482,812,065
Cash received from non-operating income	31.00	4,409,976	5,156,011
Cash Paid to Suppliers	32.00	(93,462,504)	(275,850,412)
Cash Paid to Employees	33.00	(161,482,817)	(146,078,924)
Cash Paid for Others	34.00	(26,920,740)	(23,357,390)
Cash payment for Financial Expenses		(3,153,828)	(2,268,721)
Income Tax Paid		(2,336,308)	(6,981,154)
Net cash flows from operating activities (A)*	37.00	36,062,338	33,431,475
Cash flows from Investing Activities			
Acquisition of Property, Plant and Equipment		-	(2,760,945)
Cash Payments for Capital Work-in-progress		(5,192,677)	(4,480,383)
Cash received/Payments from/to FDR		4,894,890	64,972,051
Net cash inflows/(outflows) used in investing activities (B)		(297,787)	57,730,723
Cash flows from Financing Activities			
Short Term Loan received/(Repaid)		(9,914,645)	(13,595,813)
Cash payment towards lease liabilities		(1,297,291)	(1,577,614)
Cash Dividend Paid		(6,713,709)	(13,849,321)
Net cash inflows/(outflows) provided financing activities (C)		(17,925,645)	(29,022,748)
Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)		17,838,906	62,139,450
Cash and Cash Equivalents at the beginning of the period		38,692,915	28,642,612
Cash and Cash Equivalents at the end of the period		56,531,821	90,782,062
Net Operating Cash Flow Per Share (NOCFPS)	35.00	0.26	0.24
Number of Shares used to compute NOCFPS		136,500,000	136,500,000


*Refer to Note 39.00 for a reconciliation between net profit with cash flows from operating activities.

The annexed notes from an integral part of these financial statements.


Chairman


Managing Director / CEO (CC)


Director


Chief Financial Officer


Company Secretary

Place: Dhaka;
Dated: April 28, 2025

Silva Pharmaceuticals Limited
Selected Notes to the Financial Statements (Un-Audited)
For the Third Quarter ended 31 March, 2025

1.00 About the Company

1.01 Formation and Legal Status:

Silva Pharmaceuticals Limited (the 'Company') was incorporated in Bangladesh on 24 April 2001 as a Private Limited Company and subsequently converted into Public Limited Company on 22 April, 2014 under the Companies Act, 1994 vide Registration No. CH-42959(2318)/2001 dated 24 April 2001. The Company started its commercial operation on 01st July, 2003. The Company went for Initial Public Offering (IPO) in 2018. The company is a publicly traded company and is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchanges Limited (CSE) since 10th October, 2018.

1.02 Address of the Registered Office and Factory:

The registered and corporate office of the company is located at House # 65, Road No. 8/A (New), Dhanmondi, Dhaka-1209, Bangladesh.

Factory of the company is situated at 137, Joykrishnapur, Main Road, Maijdee Court, Noakhali.

1.03 Nature of Business:

The Company has engaged in manufacturing and marketing of pharmaceuticals finished products in the categories of Antibiotics, Analgesics, Anti diabetics, Narcotics, Anti pyretic, Anti inflammatory Drugs, Anti ulcerants, Antiemetic, Gastroprokinetic, Anti histamine, Anti spasmodic expectorants, Vitamins & Minerals medicines which is selling mainly in local market.

2.00 Basis of Preparation of Financial Statements

2.01 Basis of Preparation and presentation of Interim Financial Statements

The Financial Statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs) and the International Accounting Standards (IAS) as adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and subsequently adopted by the Financial Reporting Council, Bangladesh and in compliance with other relevant local laws including the Securities and Exchange Rules, 1987. The presentation of the interim financial statements and the accounting policies used in preparing them are consistent with those of the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

2.02 Statement of Compliance

The Financial Statements have been prepared on accrual basis in accordance with generally accepted accounting principle and practice in Bangladesh in compliance with the Companies Act, 1994, the Bangladesh Securities and Exchange Rules, 2020, The Financial Reporting Act, 2015, the Listing Regulation of Dhaka Stock Exchange Limited (DSE) and Chitagong Stock Exchange Limited (CSE) 2015 and International Financial Reporting Standards (IFRSs) as adopted by the Financial Reporting Council, Bangladesh and other relevant laws and regulations applicable in Bangladesh.

2.03 Application of Standards (IAS's)

As per para 14(2) of the Securities and Exchange Rules 2020, the company have been applied in the preparation of the financial statements for the period from July 2024 to March 2025 with the following International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) as adopted by The Financial Reporting Council (FRC), Bangladesh.

Name of the Accounting Standards	Reference No.
International Accounting Standards (IASs)	
Presentation of Financial Statements	IAS-1
Inventories	IAS-2
Statement of Cash Flows	IAS-7
Accounting Policies, Changes in Accounting Estimates and Errors	IAS-8
Events after the Reporting period	IAS-10
Income Taxes	IAS-12
Property, Plant & Equipment	IAS-16
Employee Benefits	IAS-19
The Effects of Changes in Foreign Exchange Rates	IAS-21
Borrowing Costs	IAS-23
Related Party Disclosures	IAS-24
Financial instruments: Presentation	IAS-32
Earnings Per Share	IAS-33
Interim Financial Reporting	IAS-34
Impairment of assets	IAS-36
Provisions, Contingent Liabilities and Contingent Assets	IAS-37
Intangible Assets	IAS-38
International Financial Reporting Standards (IFRSs)	
Financial Instruments: Disclosure	IFRS-7
Operating Segments	IFRS-8
Financial Instruments	IFRS-9
Fair Value Measurement	IFRS-13
Revenue from Contracts with Customers	IFRS-15
Leases	IFRS-16

3.00 Property, Plant and Equipment

31 March, 2025

Particulars	Cost			Rate (%)	Depreciation			Written Down Value as at 31 March, 2025
	Balance as on 01 July, 2024	Addition during the period	Balance as on 31 March, 2025		Balance as on 01 July, 2024	Charge during the period	Balance as on 31 March, 2025	
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	-	342,774,940
Plant & Machinery	692,749,945	-	692,749,945	10%	454,752,827	17,849,784	472,602,611	220,147,334
Generator	12,396,170	-	12,396,170	10%	10,062,287	175,041	10,237,328	2,158,842
Building Decoration	121,235,416	-	121,235,416	10%	62,229,162	4,425,469	66,654,631	54,580,785
Electrical Installation	39,471,371	-	39,471,371	10%	17,966,036	1,612,900	19,578,936	19,892,435
Gas Installation	389,890	-	389,890	10%	321,650	5,118	326,768	63,122
Office Equipment	58,689,497	-	58,689,497	10%	31,068,853	2,083,145	33,151,998	25,537,499
Factory Equipment	64,741,123	-	64,741,123	10%	35,526,245	2,206,682	37,732,927	27,008,196
Furniture and Fixture	49,486,298	-	49,486,298	10%	30,177,110	1,452,015	31,629,125	17,857,173
Vehicle	129,904,291	-	129,904,291	20%	109,305,717	3,089,786	112,395,503	17,508,788
Power House	1,195,705	-	1,195,705	10%	996,894	14,911	1,011,805	183,900
Laboratory Equipment	99,725,018	-	99,725,018	10%	43,060,321	4,280,417	47,340,738	52,384,280
Factory Building & Warehouse	424,089,619	-	424,089,619	2.5%	91,217,538	6,241,352	97,458,890	326,630,729
Total as on 31 March, 2025	2,036,849,283	-	2,036,849,283		886,684,640	43,436,620	930,121,260	1,106,728,023
Total as on 30 June, 2024	1,978,065,885	58,783,398	2,036,849,283		827,896,459	58,788,181	886,684,640	1,150,164,643

Allocation of Depreciation		01 July 2024 to 31 March, 2025	01 January 2025 to 31 March, 2025
Charged during the period		43,436,620	14,519,909
Adjustment during the period		-	-
		43,436,620	14,519,909
(a) Depreciation charged to cost of sales (Note-21.00)		40,396,057	13,503,516
(b) Depreciation charged to administrative expenses (Note-22.00)		2,606,197	871,194
(c) Depreciation charged to selling & distribution expenses (Note-23.00)		434,366	145,199
Total		43,436,620	14,519,909

31 March, 2024

Particulars	Cost			Rate (%)	Depreciation			Amount in Taka
	Balance as on 01 July, 2023	Addition during the period	Balance as on 31 March, 2024		Balance as on 01 July, 2023	Charge during the period	Balance as on 31 March, 2024	Written Down Value as at 31 March, 2024
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	-	342,774,940
Plant & Machinery	636,753,992	-	636,753,992	10%	433,490,672	15,244,749	448,735,421	188,018,571
Generator	12,396,170	-	12,396,170	10%	9,802,967	194,490	9,997,457	2,398,713
Building Decoration	121,235,416	-	121,235,416	10%	55,672,911	4,917,188	60,590,099	60,645,317
Electrical Installation	39,471,371	-	39,471,371	10%	15,576,554	1,792,111	17,368,665	22,102,706
Gas Installation	389,890	-	389,890	10%	314,068	5,687	319,755	70,135
Office Equipment	58,230,177	432,820	58,662,997	10%	28,028,885	2,276,694	30,305,579	28,357,418
Factory Equipment	64,364,865	376,258	64,741,123	10%	32,294,236	2,420,863	34,715,099	30,026,024
Furniture and Fixture	49,393,811	92,487	49,486,298	10%	28,035,108	1,605,729	29,640,837	19,845,461
Vehicle	129,904,291	-	129,904,291	20%	104,156,073	3,862,233	108,018,306	21,885,985
Power House	1,195,705	-	1,195,705	10%	974,804	16,568	991,372	204,333
Laboratory Equipment	97,865,638	1,859,380	99,725,018	10%	36,867,825	4,605,401	41,473,226	58,251,792
Factory Building & Warehouse	424,089,619	-	424,089,619	2.5%	82,682,356	6,401,386	89,083,742	335,005,877
Total as on 31 March, 2024	1,978,065,885	2,760,945	1,980,826,830		827,896,459	43,343,099	871,239,558	1,109,587,272

Allocation of Depreciation

Charged during the period
Adjustment during the period

- (a) Depreciation charged to cost of sales (Note-21.00)
(b) Depreciation charged to administrative expenses (Note-22.00)
(c) Depreciation charged to selling & distribution expenses (Note-23.00)
Total

01 July 2023 to 31 March, 2024

43,343,099

43,343,099

40,309,082

2,600,586

433,431

43,343,099

01 January 2024 to 31 March, 2024

14,476,422

14,476,422

13,463,073

868,585

144,764

14,476,422

3(A) Tax Base Value of Property, Plant and Equipment

31 March, 2025

Particulars	Cost			Rate (%)	Depreciation			Written Down Value as at 31 March, 2025
	Balance as on 01 July, 2024	Addition during the year	Balance as on 31 March, 2025		Balance as on 01 July, 2024	Charge during the year	Balance as on 31 March, 2025	
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	-	342,774,940
Plant & Machinery	692,749,945	-	692,749,945	20%	589,997,835	15,412,817	605,410,652	87,339,293
Generator	12,396,170	-	12,396,170	20%	12,009,381	58,018	12,067,399	328,771
Building Decoration	121,235,416	-	121,235,416	20%	95,284,221	3,892,679	99,176,900	22,058,516
Electrical Installation	39,471,371	-	39,471,371	20%	30,126,901	1,401,671	31,528,572	7,942,799
Gas Installation	389,890	-	389,890	20%	379,967	1,488	381,455	8,435
Office Equipment	60,598,717	-	60,598,717	20%	46,918,839	2,051,982	48,970,821	11,627,896
Factory Equipment	64,741,123	-	64,741,123	10%	37,172,815	2,067,623	39,240,438	25,500,685
Furniture and Fixture	49,486,298	-	49,486,298	10%	31,112,598	1,378,028	32,490,626	16,995,672
Vehicle	129,904,291	-	129,904,291	20%	111,800,443	2,715,577	114,516,020	15,388,271
Power House	1,195,705	-	1,195,705	20%	1,164,369	4,700	1,169,069	26,636
Laboratory Equipment	99,725,018	-	99,725,018	20%	68,251,352	4,721,050	72,972,402	26,752,616
Factory Building & Warehouse	424,089,619	-	424,089,619	10%	266,545,440	11,815,813	278,361,253	145,728,366
Total as on 31 March, 2025	2,038,758,503	-	2,038,758,503		1,290,764,161	45,521,446	1,336,285,607	702,472,896
Total as on 30 June, 2024	1,979,975,105	58,783,398	2,038,758,503		1,217,721,283	73,042,878	1,290,764,161	747,994,342

31 March, 2024

Particulars					Amount in Taka			
	Cost			Rate (%)	Depreciation			Written Down Value as at 31 March, 2024
	Balance as on 01 July, 2023	Addition during the year	Balance as on 31 March, 2024		Balance as on 01 July, 2023	Charge during the year	Balance as on 31 March, 2024	
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	-	342,774,940
Plant & Machinery	636,753,992	-	636,753,992	10%	564,309,808	10,866,628	575,176,436	61,577,556
Generator	12,396,170	-	12,396,170	10%	11,912,684	72,523	11,985,207	410,963
Building Decoration	121,235,416	-	121,235,416	10%	88,796,422	4,865,849	93,662,271	27,573,145
Electrical Installation	39,471,371	-	39,471,371	10%	27,790,784	1,752,088	29,542,872	9,928,499
Gas Installation	389,890	-	389,890	10%	377,486	1,861	379,347	10,543
Office Equipment	60,139,397	432,820	60,572,217	10%	43,498,870	2,561,002	46,059,872	14,512,345
Factory Equipment	64,364,865	376,258	64,741,123	10%	34,109,670	2,297,359	36,407,029	28,334,094
Furniture and Fixture	49,393,811	92,487	49,486,298	10%	29,071,076	1,531,142	30,602,218	18,884,080
Vehicle	129,904,291	-	129,904,291	20%	107,274,481	3,394,472	110,668,953	19,235,338
Power House	1,195,705	-	1,195,705	10%	1,156,535	5,876	1,162,411	33,294
Laboratory Equipment	97,865,638	1,859,380	99,725,018	10%	60,382,936	5,901,312	66,284,248	33,440,770
Factory Building & Warehouse	424,089,619	-	424,089,619	2.5%	249,040,531	13,128,682	262,169,213	161,920,406
Total as on 31 March, 2024	1,979,975,105	2,760,945	1,982,736,050		1,217,721,283	46,378,794	1,264,100,077	718,635,973

4.00 Intangible Assets

31 March, 2025

Particulars	Cost			Rate (%)	Amortization			Written Down Value as at 31 March, 2025
	Balance as on 01 July, 2024	Addition during the period	Balance as on 31 March, 2025		Balance as on 01 July, 2024	Charge during the period	Balance as on 31 March, 2025	
Software	1,909,220	-	1,909,220	10%	684,582	91,848	776,430	1,132,790
Total as on 31 March, 2025	1,909,220	-	1,909,220		684,582	91,848	776,430	1,132,790
Total as on 30 June, 2024	1,909,220	-	1,909,220		548,511	136,071	684,582	1,224,638

Allocation of Amortization		01 July 2024 to 31 March, 2025	01 January 2025 to 31 March, 2025
Charged during the period		91,848	30,616
Adjustment during the period		-	-
		91,848	30,616
Amortization charged to administrative expenses (Note-22.00)		91,848	30,616
Total		91,848	30,616

31 March, 2024

Particulars	Cost			Rate (%)	Amortization			Written Down Value as at 31 March, 2024
	Balance as on 01 July, 2023	Addition during the period	Balance as on 31 March, 2024		Balance as on 01 July, 2023	Charge during the period	Balance as on 31 March, 2024	
Software	1,909,220	-	1,909,220	10%	548,511	102,053	650,564	1,258,656
Total as on 31 March, 2024	1,909,220	-	1,909,220		548,511	102,053	650,564	1,258,656

Allocation of Amortization		01 July 2023 to 31 March, 2024	01 January 2024 to 31 March, 2024
Charged during the period		102,053	34,018
Adjustment during the period		-	-
		102,053	34,018
Amortization charged to administrative expenses (Note-22.00)		102,053	34,018
Total		102,053	34,018

5.00 Right of Use Assets (RoU)

Right-of-use assets (ROU) arise due to implementation of IFRS 16 from 1st July 2019. This is made up from use of building as lease of Corporate Office, Factory and Depot offices.

31 March, 2025

Particulars	Cost			Depreciation			Written Down Value as at 31 March, 2025
	Balance as on 01 July, 2024	Addition during the period	Balance as on 31 March, 2025	Balance as on 01 July, 2024	Charge during the period	Balance as on 31 March, 2025	
Right of Use Assets (RoU)	26,266,197	-	26,266,197	20,614,235	979,299	21,593,534	4,672,663
Total as on 31 March, 2025	26,266,197	-	26,266,197	20,614,235	979,299	21,593,534	4,672,663
Total as on 30 June, 2024	26,266,197	-	26,266,197	18,955,802	1,658,433	20,614,235	5,651,962

Allocation of Depreciation	01 July 2024 to 31 March, 2025	01 January 2025 to 31 March, 2025
Charged during the period	979,299	322,950
Adjustment during the period	-	-
	979,299	322,950
Depreciation charged to administrative expenses (Note-22.00)	979,299	322,950
Total	979,299	322,950

31 March, 2024

Particulars	Cost			Depreciation			Written Down Value as at 31 March, 2024
	Balance as on 01 July, 2023	Addition during the period	Balance as on 31 March, 2024	Balance as on 01 July, 2023	Charge during the period	Balance as on 31 March, 2024	
Right of Use Assets (RoU)	26,266,197	-	26,266,197	18,955,802	1,320,947	20,276,749	5,989,448
Total as on 31 March, 2024	26,266,197	-	26,266,197	18,955,802	1,320,947	20,276,749	5,989,448

Allocation of Depreciation	01 July 2023 to 31 March, 2024	01 January 2024 to 31 March, 2024
Charged during the period	1,320,947	339,344
Adjustment during the period	-	-
	1,320,947	339,344
Depreciation charged to administrative expenses (Note-22.00)	1,320,947	339,344
Total	1,320,947	339,344

Amount in Taka	
31-Mar-25	30-Jun-24

6.00 Capital Work in Progress

A) Construction work-in-progress (Building)

Opening Balance	317,671,463	287,469,184
Addition during the period	5,192,677	30,202,279
Transfer to Property, Plant and equipment	-	-
Closing Balance	322,864,140	317,671,463

B) Plant and Machinery in transit and installation

Opening Balance	-	55,995,953
Addition during the period	-	-
Transfer to Property, Plant and equipment	-	(55,995,953)
Closing Balance	-	-

Total Closing Balance

322,864,140	317,671,463
-------------	-------------

A new building is being constructed in the factory premises located at Binodpur, Sadar, Noakhali to increase the overall production capacity of The Silva Pharmaceuticals Limited which have not started commercial production yet.

7.00 Inventories

Raw Materials	286,485,345	305,261,325
Packing Materials	30,082,112	37,463,562
Spares & Tools	8,648,752	15,328,457
Promotional Materials & Gift items	17,483,245	19,324,354
Finished goods	97,524,876	109,462,185
Work in Process-Closing	6,412,482	6,361,728
Total	446,636,812	493,201,611

8.00 Trade and Other Receivable

Particulars

Trade Receivables	245,988,482	255,718,828
Accrued Interest	973,361	411,593
Closing Balance:	246,961,843	256,130,421

9.00 Advances, Deposits & Prepayments

Advances & Prepayments

Advance Income Tax	14,092,954	11,756,646
Advance against Purchase	15,934,939	15,525,452
Advance against L/C	10,678,266	17,849,625
Advance against Travelling & Others	2,764,352	2,887,756
Advance against Motor-cycle Expenses	4,628,648	4,347,485
Advance against Employee	2,460,874	1,973,449
Advance against Depot Rent	1,936,600	1,902,600
Prepayments of VAT	3,355,685	6,068,870
Total	55,852,318	62,311,883

Deposits

Security Deposit

Bakhrabad Gas System Ltd	48,610	48,610
Bangladesh T & T Board	40,600	40,600
Power Development Board	288,000	288,000
Total	377,210	377,210

Total:

56,229,528	62,689,093
------------	------------

Advances: These advances are un-secured but good and subsequently realized and/or adjusted.

Deposits: These balances represents security deposits made by the company for Gas connection, Telephone line connection & Electricity connection etc.

Amount in Taka	
31-Mar-25	30-Jun-24

There is no claim against the company, which can be acknowledge as debt.

There is no aggregate amount due from the Directors (including Managing Director) and managing agents of the company and any of them severally or jointly with any other person.

10.00 Fixed Deposits Receipts (FDR)

Jamuna Bank Ltd. Foreign Exchange branch Dhaka	20,935,860	21,272,390
Shahjalal Islami Bank Ltd. Satmosjid Road Branch, Dhaka (Short Term Investment)	62,970,928	67,529,288
Total	83,906,788	88,801,678

11.00 Cash and Cash Equivalents

Cash in Hand at factory	23,103	36,739
Cash in Hand at Head Office	261,361	33,286
Cash in Hand at Depot Office	38,981,809	17,112,951
Postal Imprest	3,065	3,065
Cash at Bank	17,262,483	21,506,874
Total:	56,531,821	38,692,915

12.00 Share Capital:

12.01 Authorized Share Capital :

15,00,00,000 ordinary shares of Tk 10/= each	1,500,000,000	1,500,000,000
--	----------------------	----------------------

12.02 Issued, subscribed and paid-up share capital:

(a) By Cash	1,300,000,000	1,300,000,000
130,000,000 Ordinary shares of Tk. 10/- each fully paid in cash		

(b) By Issue of Bonus Share	65,000,000	65,000,000
6,500,000 Ordinary shares of Tk. 10/- each fully paid-up as bonus shares		

Total 13,65,00,000 ordinary shares of Taka 10/= each.	1,365,000,000	1,365,000,000
--	----------------------	----------------------

The Composition of Shareholdings of Ordinary Shares of the company is shown below:

Category of Shareholders	31-Mar-25		30-Jun-24	
	No. of Shares	%	No. of Shares	%
Directors/Sponsors	61,716,452	45.21%	69,539,201	50.94%
Financial and other Institutions	21,730,923	15.92%	21,866,686	16.02%
Foreign	11,025	0.01%	12,850	0.01%
General Public	53,041,600	38.86%	45,081,263	33.03%
Total	136,500,000	100.00%	136,500,000	100.00%

13.00 Retained Earnings

Opening balance	890,949,495	969,084,309
Dividend for the year 2023-2024 (1% Cash excluding sponsors and directors)	(6,746,505)	(13,650,000)
Net profit after tax during the period	(77,676,858)	(64,484,814)
Closing Balance:	806,526,132	890,949,495

Amount in Taka	
31-Mar-25	30-Jun-24

14.00 Deferred Tax Liability

Deferred tax assets and liabilities have been recognised and measured in accordance with the provision of IAS 12 "Income Taxes". Related deferred tax expenses/income have been disclosed in note 27.02. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying Amount	Tax base value (*)	Taxable (Deductible) Temporary Difference	Applicable tax rate	Deferred tax Liability
31 March, 2025					
Property, Plant and Equipment	1,107,860,813	702,472,896	405,387,917	20.00%	81,077,583
Total deferred tax liabilities as on 31 March, 2022	1,107,860,813	702,472,896	405,387,917		81,077,583
Total as on 30 June, 2024					
Property, Plant and Equipment	1,151,389,281	747,994,342	403,394,939	20.00%	80,678,988
Total deferred tax liabilities for the 2020-2021	1,151,389,281	747,994,342	403,394,939		80,678,988

(*) The schedule of Tax base value of Property Plant and equipment are shown in Note 03(A) in this financial statements.

15.00 Lease Liability

Movement in lease payable

Opening Balance	4,617,962	6,024,731
Addition during the period	-	-
Finance Charge	351,992	833,331
Paid during the Period	(1,297,291)	(2,240,100)
Closing Balance	3,672,663	4,617,962
Transferred to Current Maturity	(1,074,926)	(1,182,428)
Non-Current Portion	2,597,737	3,435,534

16.00 Trade and Other Payables

Trade Payable	8,335,307	7,162,713
---------------	------------------	------------------

This represents the amount payable to suppliers of raw materials, packing materials, etc. All suppliers were paid on a regular basis.

17.00 Unclaimed Dividend

For the year 2023-2024	35,386	-
For the year 2022-2023	49,203	49,203
For the year 2021-2022	39,875	39,875
For the year 2020-2021	69,601	69,601
Interest (net off AIT & Bank charge)	15,418	18,007
Total	209,482	176,686

18.00 Short Term Finance

Jamuna Bank Limited SOD A/c. No. 0018-0133012167	18,594,325	18,602,881
SJIBL-BAI-MUAZZAL (FO)	15,851,214	14,390,343
DBBL, Account No. 1714050001188	3,348,890	14,715,850
Total	37,794,429	47,709,074

19.00 Provision for expenses

Accrued Expenses	9,939,904	9,598,318
Audit & Professional Fees	4,095,835	2,889,460
Worker's Profit Participation Fund (WPPF)	-	-
Provision for Income Tax	9,013,073	5,445,728
Total	23,048,812	17,933,506

	Amount in Taka			
	Third Quarter ended Results		Quarterly Results	
	01/07/2024 to 31/03/2025	01/07/2023 to 31/03/2024	01/01/2025 to 31/03/2025	01/01/2024 to 31/03/2024
20.00 Revenue				
Local Sales (Net)	309,278,213	477,253,256	107,643,330	174,288,258
Total:	309,278,213	477,253,256	107,643,330	174,288,258

21.00 Cost of goods sold

Raw materials consumed	91,888,502	163,136,594	35,710,191	50,957,470
Packing materials consumed	32,263,158	86,830,378	7,756,690	35,156,148
Consumable item consumed	8,374,250	16,573,752	1,737,723	5,870,728
	132,525,910	266,540,724	45,204,604	91,984,346
Work in process- Opening	6,361,728	6,357,249	6,394,273	6,394,258
Work in process- Closing	(6,412,482)	(6,295,472)	(6,412,482)	(6,295,472)
Change in work in process	(50,754)	61,777	(18,209)	98,786
Total consumption	132,475,156	266,602,501	45,186,395	92,083,132
Manufacturing Overhead	26,691,364	26,230,346	8,887,242	8,281,213
Depreciation	40,396,057	40,309,082	13,503,516	13,463,073
Cost of production	199,562,577	333,141,929	67,577,153	113,827,418
Finished goods - Opening	109,462,185	104,856,358	97,863,425	105,025,824
Finished goods - Closing	(97,524,876)	(103,748,957)	(97,524,876)	(103,748,957)
Change of finished goods stock	11,937,309	1,107,401	338,549	1,276,867
Cost of Physician Sample	(3,446,109)	(3,383,423)	(1,407,862)	(862,452)
Cost of Goods Sold	208,053,777	330,865,907	66,507,840	114,241,833

Note- 21.01

21.01 Manufacturing overhead

Salary, Wages & Allowances	14,931,205	14,408,568	4,932,617	5,128,491
Workers' benefit and welfare expense	1,024,685	418,770	435,074	125,435
Overtime	312,837	521,845	116,641	126,055
Staff Welfare Expenses	364,483	516,224	119,127	177,335
Laboratory Expenses	102,938	475,376	26,340	181,550
Postage & Stamp	19,726	18,362	7,587	6,100
Indirect materials	379,745	763,258	8,162	417,250
Electricity Bill	2,784,818	2,866,495	848,194	912,165
Gas & Water bill	177,502	209,140	59,896	64,908
Uniform and liveries	-	54,435	-	12,470
Carriage Inward	413,224	680,720	103,590	152,726
Medical Expenses	-	20,745	-	-
Power & Fuel	106,601	834,109	54,019	165,505
Printing & Stationery	442,447	76,206	244,599	21,317
Traveling & Conveyance	65,462	88,430	18,675	30,870
Factory Rent	1,080,000	1,080,000	360,000	360,000
Toll Charges	3,382,158	-	1,292,778	-
Repairs & Maintenance	829,033	2,828,226	181,531	285,682
Sanitation & Cleaning	45,031	207,152	36,090	56,452
Entertainment	229,469	162,285	42,322	56,902
Total	26,691,364	26,230,346	8,887,242	8,281,213

Amount in Taka			
Third Quarter ended Results		Quarterly Results	
01/07/2024 to 31/03/2025	01/07/2023 to 31/03/2024	01/01/2025 to 31/03/2025	01/01/2024 to 31/03/2024

22.00 Administrative Expenses

Salary, Wages & Allowances	19,745,655	18,999,596	6,336,933	6,770,803
Staff Welfare expenses	784,675	591,639	303,186	208,116
Printing & Stationery	151,409	207,329	77,564	81,549
Phone, Fax, Mobile and Internet Bill	432,246	346,841	-	99,523
Postage & Stamps	51,779	48,893	20,760	12,450
Traveling & Conveyance	652,869	121,212	77,748	34,770
Utility Bill	671,439	612,636	161,480	148,437
Entertainment	351,628	312,942	88,640	119,094
Donation and Subscription	125,400	-	-	-
Licenses Renewal and Registration Fee	97,980	198,988	19,780	19,780
Audit Fees	301,875	301,875	100,625	100,625
Directors Remuneration	500,000	900,000	-	300,000
Board meeting attending fees	253,125	267,375	65,625	86,250
Amortization of Intangible Assets	91,848	102,053	30,616	34,018
Depreciation of Right-of-use Assets	979,299	1,320,947	322,950	339,344
Depreciation	2,606,197	2,600,586	871,194	868,585
Repairs & Maintenance	779,083	491,616	207,353	137,303
RJSC Exp.	6,188	-	6,188	-
AGM Expenses	464,998	249,730	-	-
Legal & Professional fees	2,307,310	449,500	1,492,000	160,750
Total	31,355,003	28,123,758	10,182,642	9,521,397

23.00 Selling & Distribution Expenses

Salary, Wages & Allowances	103,079,258	92,856,794	35,016,034	33,106,804
Field forces expenses	18,135,215	12,826,185	5,639,781	4,033,847
Transportation & Handling Expenses	2,986,411	1,757,658	917,219	599,172
Staff Welfare expenses	1,475,801	2,246,894	310,172	697,396
Business Promotion Expenses	1,103,326	166,258	482,435	127,800
Repair & Maintenance	573,226	322,280	193,038	68,155
Traveling and conveyance Expenses	1,613,436	1,272,170	445,118	284,982
Water, electricity and Gas	413,903	446,595	118,549	134,282
Phone, Fax and Mobile Bill	158,442	338,187	33,540	115,436
Sample Expenses	3,446,109	3,383,423	1,407,862	862,452
Consumption of promotional materials	3,169,559	2,370,542	1,203,461	831,482
Postage & Courier	777,373	870,281	214,380	287,185
Entertainment	229,434	314,037	75,418	94,334
Printing & Stationery	1,226,093	1,260,078	350,080	338,412
Depot Rent	3,083,000	2,726,650	905,900	982,650
Product Development Expenses	54,500	45,700	-	700
Training Expenses	774,846	844,988	56,669	340,587
Bank Charge	396,455	1,127,054	116,350	304,384
Depreciation	434,366	433,431	145,199	144,764
Vehicle Maintenance	1,526,444	1,132,666	324,882	338,934
Loading & Unloading	221,167	266,996	66,454	91,771
License fees & Renewals	167,911	208,066	30,930	24,980
Total	145,046,275	127,216,933	48,053,471	43,810,509

24.00 Financial Expenses

Interest on Short Term Loan	3,141,651	2,186,901	1,460,003	1,245,777
Bank Charge & Commission	12,177	81,820	-	1,540
Finance Charges for lease	351,992	146,700	109,480	46,344
Total	3,505,820	2,415,421	1,569,483	1,293,661

Amount in Taka			
Third Quarter ended Results		Quarterly Results	
01/07/2024 to 31/03/2025	01/07/2023 to 31/03/2024	01/01/2025 to 31/03/2025	01/01/2024 to 31/03/2024

25.00 Other Income

Interest on FDR	4,486,952	3,270,019	1,418,840	1,386,412
Interest on Bank STD Accounts	4,337	159,254	1,951	-
Miscellaneous Income	480,455	816,084	185,460	317,584
	4,971,744	4,245,357	1,606,251	1,703,996

26.00 Workers Profit Participation and Welfare Fund (WPP&WF)

Net Profit before Contribution to WPPF&WF	(73,710,918)	(7,123,406)	(17,063,855)	7,124,854
Rate of contribution to WPPF(%)	5.00%	5.00%	5.00%	5.00%
Workers Profit Participation and Welfare Fund (WPPF)	-	-	-	-

Note: Allocation for workers' profit participation fund has been made @ 5% of profit after charging such expenses as per provisions of the Bangladesh Labour Act, 2006 (Amendment 2013).

27.00 Income Tax expenses:

27.01 Current Tax Expenses

Net Profit before Income Tax	(72,986,835)	(7,123,406)	(16,339,772)	7,124,854
Accounting Depreciation	43,528,468	43,445,152	14,550,525	14,510,440
Tax Depreciation	(45,521,446)	(46,378,794)	(15,173,814)	(15,474,850)
Taxable Profit	(74,979,813)	(10,057,048)	(16,963,061)	6,160,444
Tax Rate	20.00%	20.00%	20.00%	20.00%
Current Tax Expenses during the period	(14,995,963)	(2,011,410)	(3,392,613)	1,232,088
Current Tax Expenses for the previous Assessment year	-	-	-	-
Total Current Tax Expenses	(14,995,963)	(2,011,410)	(3,392,613)	1,232,088

Minimum Tax Calculation

Calculation of Gross Receipts

Revenue from net sales	309,278,213	477,253,256	107,643,330	174,288,258
Other Income				
Interest on FDR	4,486,952	3,270,019	1,418,840	1,386,412
Interest on Bank deposit	4,337	159,254	1,951	-
Other Income	480,455	816,084	185,460	317,584
Total Gross Receipts	314,249,957	481,498,613	109,249,581	175,992,254
Minimum Tax (0.60% on total gross receipts except Interest income)	1,858,552	2,888,992	646,973	1,055,954
AIT paid on Interest income and Vehicle (As minimum Tax)	1,708,793	-	805,040	-
Total Minimum Tax	3,567,345	2,888,992	1,452,013	1,055,954
Income Tax Provision whichever is higher	3,567,345	2,888,992	1,452,013	1,055,954

Income tax provision is higher between tax at regular rate on income and minimum tax on gross receipts U/S 163 (6) of Income Tax Act, 2023. Hence tax at regular rate is accounted for as it is higher than the minimum tax.

27.02 Deferred Tax Expenses/(Income)

Closing balance of deferred tax liability	Note- 14	81,077,583	78,441,991	81,077,583	78,441,991
Opening balance of deferred tax liability	Note- 14	(80,678,988)	(77,855,263)	(80,952,926)	(77,990,574)
Deferred Tax Expenses/(Income)		398,595	586,728	124,657	451,417

28.00 Earnings per Share

Net profit after Tax (Numerator)	(77,676,858)	(10,599,126)	(18,640,525)	5,617,483
Number of Ordinary Shares (Denominator)	136,500,000	136,500,000	136,500,000	136,500,000
Basic Earnings per Share (EPS)	(0.57)	(0.08)	(0.14)	0.04

There is no potential dilutive claim during the period. Hence no diluted EPS has been calculated during the reporting period.

		<i>Amount in Taka</i>	
		31-Mar-25	30-Jun-24
29.00 Net Asset Value (NAV) Per Share			
Total Assets		2,325,664,408	2,414,228,424
Less: Total Liabilities		154,138,276	158,278,929
Net Asset Value		2,171,526,132	2,255,949,495
Total Number of Share outstanding		136,500,000	136,500,000
Net Asset Value (NAV) Per Share		15.91	16.53
30.00 Cash received from Customers		01/07/2024 to 31/03/2025	01/07/2023 to 31/03/2024
Sales during the year		309,278,213	477,253,256
Opening Trade Receivable		255,718,828	257,346,620
Closing Trade Receivable		(245,988,482)	(251,787,811)
Total Cash Received from Customers		319,008,559	482,812,065
31.00 Cash received from non-operating income			
Other income		4,971,744	4,245,357
Opening interest receivable		411,593	1,972,765
Closing interest receivable		(973,361)	(1,062,111)
Total Cash received from non-operating income		4,409,976	5,156,011
32.00 Cash Paid to Suppliers			
Purchase (Raw, Packing, Promotional, Indirect material and		101,396,970	266,409,556
Opening Accounts Payable		7,162,713	6,989,159
Closing Accounts Payable		(8,335,307)	(7,751,605)
Closing Advance against Purchase & L/C		26,613,205	38,862,850
Opening Advance against Purchase & L/C		(33,375,077)	(28,659,548)
Total Cash Paid to Suppliers		93,462,504	275,850,412
33.00 Cash Paid to Employees			
Salary, Wages & Allowances including contribution to PF		140,381,077	129,619,715
Workers' benefit and welfare expense		1,024,685	418,770
Overtime		312,837	521,845
Directors Remuneration		500,000	900,000
Board meeting attending fees		253,125	267,375
Field forces expenses		18,135,215	12,826,185
Worker's Profit Participation and Welfare Fund		-	2,518,229
Opening Payable		8,429,371	7,905,969
Closing Payable		(8,040,918)	(8,813,034)
Closing Advance to Employee		2,460,874	1,786,522
Opening Advance to Employee		(1,973,449)	(1,872,652)
Total Cash Paid to Employees		161,482,817	146,078,924
34.00 Cash Paid for Others			
Manufacturing Overhead (excluding pay to employee & Supplier)		9,678,409	9,601,681
Administrative Overhead (excluding Depreciation & pay to employee)		6,394,204	3,341,562
Selling and Distribution overhead (excluding sample, promotional, Depreciation & pay to employee)		15,305,967	13,099,664
Opening Liabilities for Expenses		4,058,407	3,158,955
Closing Liabilities for Expenses		(5,994,821)	(4,701,388)
Closing Advance deposit & prepayment		13,062,495	16,725,720
Opening Advance deposit & prepayment		(15,583,921)	(17,868,804)
Total Cash Paid for Others		26,920,740	23,357,390
35.00 Net Operating Cash Flow Per Share(NOCFPS)			
Net Operating Cash Flow		36,062,338	33,431,475
Weighted Average Number of Ordinary Shares (Denominator)		136,500,000	136,500,000
Net Operating Cash Flow Per Share(NOCFPS)		0.26	0.24

36.00 Disclosure as per requirement of the Companies Act, 1994

36.01 Disclosure as per Schedule XI, part I, para 4 of the Companies Act, 1994 are given below:

Sl. No.	Particulars	31-Mar-25	30-Jun-24
		Amount in Taka	
I	Receivables considered good and in respect of which the company is fully secured.	-	-
II	Receivables considered good for which the company holds no security other than the debtor's personal security.	245,988,482	255,718,828
III	Receivables considered doubtful or bad.	-	-
IV	Receivables due by directors or other officers of the company or any of them either severally or jointly with any other person or receivables due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
V	Receivables due by companies under the same management.	-	-
VI	The maximum amount due by directors or other officers of the company at any time during the year.	-	-
Total:		245,988,482	255,718,828

36.02 Disclosure as per Schedule XI, part I, para 6 of the Companies Act, 1994 are given below:

Sl. No.	Particulars	31-Mar-25	30-Jun-24
		Amount in Taka	
I	Advances, Deposits and Prepayments considered good and in respect of which the company is fully secured.	-	-
II	Advances, Deposits and Prepayments considered good for which the company holds no security.	46,375,654	53,480,403
III	Advances, Deposits and Prepayments considered doubtful or bad.	-	-
IV	Advances, Deposits and Prepayments due by directors or other officers of the company or any of them either severally or jointly with any other person or Advance, Deposits and Prepayment due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
V	Advance, Deposits and Prepayment due by companies under the same management.	-	-
VI	The maximum amount due by directors or other officers of the company at any time during the year.	9,853,874	9,208,690
Total:		56,229,528	62,689,093

36.03 Disclosure of Schedule XI, Part II, Para 3, of the Companies Act, 1994 are given below:

I. a. Turnover:

Particulars	01/07/2024 to 31/03/2025	
	Quantity (Pcs/PHs)	Amount in Taka
Tablet	40,008,018	168,710,270
Capsule	9,134,775	49,243,697
Liquid	899,150	63,617,629
Dry Syrup	366,199	27,706,617
Total	50,408,142	309,278,213

b. No Commission paid to selling agents during the period.

c. No brokerage and discount paid on sales, other than the usual trade discount during the period.

d. (i) Raw Materials consumed:

Particulars	01/07/2024 to 31/03/2025	
	Quantity (KG)	Amount in Taka
Opening stock	210,168	305,261,325
Purchase	39,622	73,112,522
Raw material available for consumption	249,790	378,373,847
Closing stock	(145,546)	(286,485,345)
Total Raw material consumed	104,245	91,888,502

(ii) Finished goods:

Particulars	01/07/2024 to 31/03/2025		
	Opening Qty.	Production Qty.	Closing Qty.
Tablet (Pcs.)	16,521,477	45,536,500	22,049,959
Capsule (Pcs.)	6,418,438	11,373,000	8,656,663
Liquid (PHs.)	172,708	986,500	260,058
Dry Syrup (PHs.)	139,868	709,500	483,169
Total	23,252,491	58,605,500	31,449,849

II. Disclosure as per requirement of Schedule XI, Part II, Note-5 of Para 3, of the Companies Act, 1994 are given below:

Employee Position of SILVA PHARMACEUTICALS LTD. as at 31 March, 2025

Salary Range (Monthly)	Total Employee	Officer & Staff		Worker & Employee	
		Head Office	Factory	Field	Factory
Number of Employees whose salary below taka 3,000 or 5,500 p.m.	-	-	-	-	-
Number of Employees whose salary above taka 3,000 or 5,500 p.m.	688	49	24	524	91
Total	688	49	24	524	91

36.04 Disclosure as per requirement of schedule XI, part II, Para 4 are given below:

01 July 2024 to
31 March, 2025

(a) Managerial Remuneration paid or payable during the financial period to the directors, including managing directors, a managing agent or manager;	500,000
(b) Expenses re-imbursed to the Managing Agent;	Nil
(c) Commission or Other Remuneration payable separately to a managing agent or his associate;	Nil
(d) Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company.;	Nil
(e) The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial period.;	Nil
(f) Any other perquisite or benefits in cash or in kind stating, approximate money value where practicable ;	253,125
(g) Other allowances and commission including guarantee commission.	Nil
(h) Pensions etc.	
(i) Pensions	Nil
(ii) Gratuities	Nil
(iii) Payments from a provident funds, in excess of own subscription and interest thereon	Nil
(iv) Compensation for loss of office	Nil
(v) Consideration in connection with retirement from office.	Nil

36.05 Disclosure as per requirement of schedule XI, Part II, Para 7 are given below:

Capacity utilization of SILVA PHARMACEUTICALS LTD. For the period ended 31 March, 2025

Name of Item	Installed Capacity	Actual Production	% of Capacity Utilization
	Million Pcs/Ph.	Million Pcs/Ph.	
Tablet	150	45.54	30.36%
Capsule	43.50	11.37	26.14%
Liquid	1.5	0.99	65.77%
Dry Syrup	1.35	0.71	52.56%
Total	195.225	58.61	30.02%

36.06 Disclosure as per requirement of schedule XI, part II, Para 8 are given below:

- a) Value of imports calculated on C.I.F basis by the company during the financial period ended 31 March, 2025 in respect of Raw materials, Component and Spare parts and Capital Goods were as follows:

Sl. No.	Particulars	Import		
		Unit	Quantity	Amount in BDT
i	Raw Materials	Kg/Ltr.	775	6,727,738
ii	Packing Materials	Pcs/Kg	6,199	8,429,742
iii	Components and Spare parts	Set	-	-
iv	Capital Goods	Set/Unit	-	-
Total			6,974	15,157,480

- b) The Company did not have any expenditure in foreign currency during the period on account of Royalty, Know-how, Professional consultation fees, Interest and other matters.
- c) Value of all imported raw materials, spare parts and components consumed during the financial period and the value of all indigenous raw materials, spare parts and components similarly consumed and the percentage of each to the total consumption were as follows:

Particulars	Imported Value (in BDT)	Imported in percentage (%)	Indigenous Value (in BDT)	Indigenous in percentage(%)	Total
Raw Materials	50,147,385	54.57%	41,741,117	45.43%	91,888,502
Packing Materials	8,309,363	25.75%	23,953,795	74.25%	32,263,158
Components and Spare parts	-	0.00%	8,374,250	100.00%	8,374,250
Total	58,456,748	44.11%	74,069,162	55.89%	132,525,910

- d) No amount has been remitted during the period in foreign currencies on account of dividends for non-residents shareholders,
- e) Earnings in foreign exchange classified under the following heads as follows:
- No export made during the period;
 - No royalty, know-how, professional and consultation fees were received;
 - No Interest and Dividend received;
 - No Other income received

37.00 Reconciliation of Net income with Cash Flows from Operating Activities

Particulars	01/07/2024 to 31/03/2025	01/07/2023 to 31/03/2024
Net Profit before Income tax	(73,710,918)	(7,123,406)
Adjustment for:		
Depreciation	44,415,919	44,664,046
Amortization	91,848	102,053
Finance Expense for lease	351,992	146,700
	44,859,759	44,912,799
Decrease (Increase) in Advances, deposits & Prepayments.	8,795,873	(8,974,088)
Decrease (Increase) in Trade & Other Receivable	9,168,578	6,469,463
Increase (Decrease) in Accounts and Other Payable	1,172,594	762,446
Increase (Decrease) in Provision and Accruals	1,547,961	(68,731)
Decrease (Increase) in Inventories	46,564,799	4,434,146
Income Tax Paid	(2,336,308)	(6,981,154)
Net Cash Generated From Operating activities (indirect method)	36,062,338	33,431,475
Net Cash Generated From Operating activities (Direct method)	36,062,338	33,431,475

38.00 Disclosures as per IAS 24 Related Party disclosures are as follows:

The company carried out a number of transaction with related parties. The following are the related parties transactions of Silva pharmaceuticals Limited has been disclosed as required by IAS 24 Related Party Disclosures:

38.01 Disclosures as per paragraph 17 of IAS 24 are as follows:

(a) Short term employee benefits:

(a) Short term employee benefits:				
Name of the Related Parties	Nature of Relationship	Nature of Transaction	Value of goods / Services received during the period	Balance payable as on 31.03.2025
Dr. Saira Khan	Managing Director	Remuneration	500,000	-
		Board Meeting Fees	25,875	-
Mrs. Silvana Mirza	Chairman	Board Meeting Fees	25,875	-
Mrs. Samina Mirza	Director	Board & AC Meeting Fees	51,750	-
Mrs. Farhana Mirza	Director	Board & NRC Meeting Fees	8,625	-
Md. Monsur Rahman (Representative of Adarsha Fisheries & Poultry Farms Ltd.)	Director	Board, AC & NRC Meeting Fees	51,750	-
Mahmuda Akhter (Representative of ICB)	Director	Board Meeting Fees	25,875	-
Md. Musfiqur Rahman, FCA	Independent Director	Board & AC Meeting Fees	51,750	-
Muhammad Moniruzzaman, FCA	Independent Director	Board & NRC Meeting Fees	25,875	-
Mr. A. R. Hassan Mirza	Executive Director & Sponsor Shareholder	Salary & Allowances	2,700,000	300,000
		Office Rent	1,195,290	132,810
Total			4,662,665	432,810

- (b) Post-employment benefits
- ⊙ Other long term benefits
- (d) Termination benefits and
- (e) Share-based payment

01/07/2024 to 31/03/2025
Nil
Nil
Nil
Nil

39.00 Significant Deviation

During the reported period from July 1, 2024 to March 31, 2025 the Net profit after tax and Earnings per Share (EPS) are decreased comparison to the same period of the previous year due to increase in cost of goods sold for disruption of global supply chain caused increase of all input raw material (Local and imported) price caused by appreciation of US Dollar against BDT, increase of utility cost and other relevant overhead and also decrease in the sales volume as compared to the previous year same period. NOCFPS increased due to sales revenue collections was increased during July 2024 to March 2025 period. The NAV per share has decreased due to net loss occurred during the period.